ArticleACS omega2026
Development of a Dual-Drug-Loaded Bone Cement with Osteogenic Potential and Antibiotic Release.
Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To address the dual challenges of poor osteogenesis and postoperative infection in bone repair, a novel calcium sulfate-based composite bone cement coloaded with osteoinductive phytochemicals (icariin (ICA) or soybean isoflavone (SI)), and the antibiotic vancomycin (VCM) was developed. The solid phase consisted of bamboo fibers and silica-reinforced calcium sulfate. This study systematically investigated the impact of drug incorporation on the material's microstructure, setting time, mechanical strength, degradation behavior, cytocompatibility, and drug release profile. Results indicated that the drugs were physically incorporated without chemical bonding to the matrix. The setting time (postdrug loading) increased from ∼12 min (drug-free control) to 13-16 min, the compressive strength decreased from 91.4 MPa to a range of 50.4-78.7 MPa, depending on the drug loading, and the optimized formulations maintained sufficient handleability and mechanical integrity. Notably, after 8 weeks of degradation, the compressive strength remained within 26-30 MPa, matching the requirements for cortical bone defect repair.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.